| | Characteristics and outcomes | EEN group () | Non-EEN group () | |
| | Gender, n | | | 0.537 | | Male | 28 | 15 | | | Female | 18 | 13 | |
| | Montreal classification of age at abscess diagnosis, n | | | 0.723 | | A1 (<16 years) | 0 | 0 | | | A2 (17–40 years) | 33 | 19 | | | A3 (>40 years) | 13 | 9 | |
| | Montreal classification of disease location, n | | | 0.912 | | L1 (ileal) | 15 | 10 | | | L2 (colonic) | 2 | 1 | | | L3 (ileocolonic) | 29 | 17 | |
| | Previous surgical history, n | 11 | 8 | 0.656 |
| | Multiple abscesses, n | 8 | 7 | 0.430 |
| | Abscess location, n | | | 0.636 | | Right lower quadrant | 20 | 13 | | | Pelvis | 16 | 7 | | | Others | 10 | 8 | |
| | Perianal lesion, n | 6 | 7 | 0.219 |
| | Abscess diameter > 3 cm, n | 11 | 11 | 0.161 |
| | Fistula | 29 | 10 | 0.022 |
| | Steroids at diagnosis, n | 14 | 14 | 0.092 |
| | AZA/6-MP at diagnosis, n | 15 | 14 | 0.137 |
| | Infliximab at diagnosis, n | 6 | 3 | 1.000 |
| | Surgical approach | | | 0.235 | | Open | 15 | 13 | | | Laparoscopy | 31 | 15 | |
| | Pre-op laboratory indices | | | | | White blood cell (×109/L), mean (range) | 6.45 (2.4–24.4) | 6.28 (3.8–14.9) | 0.836 | | Hemoglobin (g/L), mean (range) | 11.93 (7.4–14.5) | 11.18 (7.1–12.7) | 0.100 | | ESR (mm/h), mean (range) | 17.82 (0–74) | 34.86 (5–72) | <0.001 | | C-reactive protein (mg/L), mean (range) | 8.704 (0–59.6) | 23.80 (1.2–112.1) | 0.001 | | Albumin (g/L), mean (range) | 36.05 (28.4–42.5) | 31.11 (23.1–41.3) | <0.001 |
| | Abscess resolution, n | 41 | 19 | 0.023 |
| | Post-op IASCs, n | 3 | 7 | 0.036 |
| | Stoma creation, n | 20 | 13 | 0.804 |
| | Postop hospital stay (days), mean (±SD) | 9.65 ± 6.75 | 13.64 ± 8.84 | 0.032 |
| | Operative time (min), mean (±SD) | 203.63 ± 69.04 | 198.57 ± 52.38 | 0.740 |
| | Intraoperative bleeding (ml), mean (±SD) | 87.94 ± 67.94 | 86.07 ± 57.18 | 0.904 |
|
|
